Navigation Links
Provenance Biopharmaceuticals Corp. Announces $8M Financing Arrangement

WALTHAM, Mass., Dec. 22, 2011 /PRNewswire/ -- Provenance Biopharmaceuticals Corp. ("Provenance") announced today the closing of an $8 million financing arrangement with Alopexx Enterprises, LLC for the continued development of anti-cancer therapeutic, DI-Leu16-IL2.

DI-Leu16-IL2 is among a class of molecules called immunocytokines that are being developed for the treatment of various forms of cancer.  Immunocytokines, combine the immune stimulating features of cytokines with the targeting properties of antibodies. DI-Leu16-IL2, Provenance's most advanced program, is a de-immunized form of an anti-CD20 antibody, Leu16, genetically fused to the cytokine, interleukin 2 (IL2). DI-Leu16-IL2 is being studied for the treatment of non-Hodgkin's lymphoma and other forms of hematological cancer and is currently in an investigator sponsored Phase I clinical trial.

Under the terms of the financing, Provenance and Alopexx Enterprises, LLC have formed a new company, Alopexx Oncology, LLC to manage the clinical development of DI-Leu16-IL2. Financial details of the transaction are not disclosed.

About Provenance Biopharmaceuticals Corp.

Provenance is a clinical-stage biotechnology company focused on developing novel therapeutics for cancer and other serious, life-threatening diseases. The Company's engineered antibody technologies promote the body's own immune system to recognize and fight disease. In addition to DI-Leu16-IL2, Provenance has several additional early-stage molecules in development. For more information, please go to

About Alopexx Enterprises, LLC.

Alopexx Enterprises, LLC is a healthcare company focused on acquiring and developing preclinical and early clinical compounds, with an emphasis on infectious diseases, oncology, and CNS.  It was founded in 2011 by highly experienced pharmaceutical executives and leverages the unique insights and experiences of its founders and world-class scientific advisors. Beyond the financial investment the group is able to offer hands-on expertise in pre-clinical development, manufacturing, regulatory affairs, logistics, clinical development and partnering.  For more information please go to

SOURCE Provenance Biopharmaceuticals Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Inspiration Biopharmaceuticals Expands Leadership Team with Four New Hires
2. Keryx Biopharmaceuticals Announces Phase 2 Data for KRX-0401 (Perifosine) in Hodgkins Lymphoma Presented at ASH Meeting
3. Inspiration Biopharmaceuticals Presents Key Scientific Data from its Two Lead Hemophilia Development Programs at the 53rd Annual Meeting of the American Society of Hematology (ASH)
4. Inspiration Biopharmaceuticals Initiates Second Pivotal Clinical Study of Innovative Hemophilia Therapy OBI-1
5. Keryx Biopharmaceuticals Announces Highlights from Zerenex™ (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting
6. Keryx Biopharmaceuticals to Present at Lazard Capital Markets 8th Annual Healthcare Conference
7. Planet Biopharmaceuticals, Inc. Divests Assets of Allergy Control Products, Inc.
8. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2011 Financial Results
9. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Third Quarter 2011 Financial Results
10. Inspiration Biopharmaceuticals Names John P. Butler Chief Executive Officer
11. CMC Biologics Enters Commercial Supply Agreement with Inspiration Biopharmaceuticals for IB1001
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in Bogota. Colombia ... ... Sandra ... ... Astellas is a pharmaceutical company ...
(Date:6/23/2016)... , June 23, 2016  Experian Health, ... and transforming the patient payment and care ... innovative new products and services that will ... revenue cycle offerings. These award-winning solutions will ... workflows, remain compliant in an ever-changing environment ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
Breaking Medicine News(10 mins):